Stocks · News reference
Insmed Announces 12-Month TPIP OLE Data Demonstrating Sustained Improvement, Mortality Risk Reduction, And No Newly Identified Safety Signals In PAH
–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0––Placebo Crossed Group Demonstrated Treatment Response
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 16, 2026, 11:03 AM
- Checked
- Jul 16, 2026, 11:03 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Biotech Is Booming, But These 2 Stocks Missed the Memo
The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.
Read original at benzingaJP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175
JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $179 to $175.
Read original at benzingaTruist Securities Reiterates Buy on Insmed, Raises Price Target to $195
Truist Securities analyst Danielle Brill reiterates Insmed (NASDAQ:INSM) with a Buy and raises the price target from $185 to $195.
Read original at benzinga